Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.

Regeneron Pharmaceuticals ... Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in …

6 days ago · After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this summer—the lowest they’d been since …

Regeneron is a leading biotechnology company dedicated to inventing, developing and commercializing life-transforming medicines for people with serious diseases.

Dec 8, 2025 · Regeneron is proposing less onerous regimens in its bid to move T-cell engagers Lynozyfic and Ordspono into earlier lines of blood cancer treatment.

We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® (RGC) and pioneering genetic medicine platforms, enabling us to identify …

Dec 8, 2025 · Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin. Moreover, as of September 30, Regeneron had about $2.2 billion …

5 days ago · A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to …

2 days ago · Look beyond the healthcare company's recent setbacks. Arguably, the biggest reason why Regeneron's shares dropped is that competition has intensified for Eylea, its …

Dec 7, 2025 · Quiver AI Summary Regeneron Pharmaceuticals announced promising interim results from its Phase 1/2 LINKER-MM4 trial, which evaluated the efficacy of its bispecific …